Benitec Biopharma (NASDAQ:BNTC) Upgraded to “Hold” at Wall Street Zen

Posted by George Bondi on Aug 2nd, 2026

Wall Street Zen upgraded shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) from a sell rating to a hold rating in a research note released on Saturday.

BNTC has been the topic of a number of other research reports. Guggenheim cut Benitec Biopharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 10th. Evercore initiated coverage on shares of Benitec Biopharma in a research report on Tuesday, May 12th. They set an “outperform” rating and a $25.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Friday, July 17th. Finally, Wedbush initiated coverage on shares of Benitec Biopharma in a research note on Tuesday. They set an “outperform” rating and a $16.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.80.

Get Our Latest Stock Report on Benitec Biopharma

Benitec Biopharma Price Performance

Shares of NASDAQ:BNTC opened at $11.71 on Friday. The business’s 50 day simple moving average is $12.03 and its 200 day simple moving average is $11.81. Benitec Biopharma has a 1 year low of $9.85 and a 1 year high of $16.76. The company has a market capitalization of $402.24 million, a P/E ratio of -10.27 and a beta of 0.25.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.03. On average, sell-side analysts anticipate that Benitec Biopharma will post -1.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

A number of large investors have recently modified their holdings of the business. RA Capital Management L.P. bought a new stake in shares of Benitec Biopharma during the 4th quarter worth $24,920,000. Suvretta Capital Management LLC boosted its stake in Benitec Biopharma by 16.9% in the fourth quarter. Suvretta Capital Management LLC now owns 11,548,351 shares of the biotechnology company’s stock valued at $155,556,000 after buying an additional 1,671,845 shares in the last quarter. Siren L.L.C. bought a new position in Benitec Biopharma in the fourth quarter valued at about $10,439,000. Alyeska Investment Group L.P. bought a new position in Benitec Biopharma in the fourth quarter valued at about $10,102,000. Finally, Balyasny Asset Management L.P. acquired a new position in Benitec Biopharma during the fourth quarter worth about $8,776,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.